Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Atreca Inc (BCEL) NPV A

Sell:$13.04 Buy:$13.05 Change: $0.1 (0.77%)
NASDAQ:1.47%
Market closed |  Prices as at close on 3 August 2020 | Switch to live prices |
Sell:$13.04
Buy:$13.05
Change: $0.1 (0.77%)
Market closed |  Prices as at close on 3 August 2020 | Switch to live prices |
Sell:$13.04
Buy:$13.05
Change: $0.1 (0.77%)
Market closed |  Prices as at close on 3 August 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Atreca, Inc. is a biotechnology company. The Company is engaged in developing therapeutics drawn from human immune responses, including anti-cancer immune responses. Its portfolio programs are focused on applications in cancer treatment. The Company’s lead product candidate, ATRC-101, is a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using our discovery platform. The Company's Immune Repertoire Capture (IRC) technology, which enables us to accurately reconstruct the original antibody sequences from a single B cell in parallel with other B cells in the sample. Its IRC tracks the co-expression of genes from the same single cell and TCRs are recovered. IRC generates sequence information from the beginning of signal sequences through constant regions of immunoglobulins, delivering variable domains and isotype information.

Contact details

Address:
450 East Jamie Court
SOUTH SAN FRANCISCO
94080
United States
Telephone:
+1 (650) 5952595
Website:
www.atreca.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BCEL
ISIN:
US04965G1094
Market cap:
$378.02 million
Shares in issue:
35.12 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Brian Atwood
    Independent Chairman of the Board
  • John Orwin
    President, Chief Executive Officer, Director
  • Herbert Cross
    Chief Financial Officer
  • Guy Cavet
    Chief Technical Officer
  • Norman Greenberg
    Chief Scientific Officer
  • Courtney Phillips
    General Counsel
  • Tito Serafini
    Chief Strategy Officer, Director
  • Lisa Decker
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.